These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 33651375

  • 1. Activation of soluble guanylyl cyclase signalling with cinaciguat improves impaired kidney function in diabetic mice.
    Harloff M, Prüschenk S, Seifert R, Schlossmann J.
    Br J Pharmacol; 2022 Jun; 179(11):2460-2475. PubMed ID: 33651375
    [Abstract] [Full Text] [Related]

  • 2. Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney.
    Stehle D, Xu MZ, Schomber T, Hahn MG, Schweda F, Feil S, Kraehling JR, Eitner F, Patzak A, Sandner P, Feil R, Bénardeau A.
    Br J Pharmacol; 2022 Jun; 179(11):2476-2489. PubMed ID: 34096053
    [Abstract] [Full Text] [Related]

  • 3. Targeted Delivery of Soluble Guanylate Cyclase (sGC) Activator Cinaciguat to Renal Mesangial Cells via Virus-Mimetic Nanoparticles Potentiates Anti-Fibrotic Effects by cGMP-Mediated Suppression of the TGF-β Pathway.
    Fleischmann D, Harloff M, Maslanka Figueroa S, Schlossmann J, Goepferich A.
    Int J Mol Sci; 2021 Mar 04; 22(5):. PubMed ID: 33806499
    [Abstract] [Full Text] [Related]

  • 4. Chronic Activation of Heme Free Guanylate Cyclase Leads to Renal Protection in Dahl Salt-Sensitive Rats.
    Hoffmann LS, Kretschmer A, Lawrenz B, Hocher B, Stasch JP.
    PLoS One; 2015 Mar 04; 10(12):e0145048. PubMed ID: 26717150
    [Abstract] [Full Text] [Related]

  • 5. The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus.
    Mátyás C, Németh BT, Oláh A, Hidi L, Birtalan E, Kellermayer D, Ruppert M, Korkmaz-Icöz S, Kökény G, Horváth EM, Szabó G, Merkely B, Radovits T.
    Cardiovasc Diabetol; 2015 Oct 31; 14():145. PubMed ID: 26520063
    [Abstract] [Full Text] [Related]

  • 6. Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension.
    Chester M, Seedorf G, Tourneux P, Gien J, Tseng N, Grover T, Wright J, Stasch JP, Abman SH.
    Am J Physiol Lung Cell Mol Physiol; 2011 Nov 31; 301(5):L755-64. PubMed ID: 21856817
    [Abstract] [Full Text] [Related]

  • 7. Inactivation of soluble guanylyl cyclase in living cells proceeds without loss of haem and involves heterodimer dissociation as a common step.
    Dai Y, Stuehr DJ.
    Br J Pharmacol; 2022 Jun 31; 179(11):2505-2518. PubMed ID: 33975383
    [Abstract] [Full Text] [Related]

  • 8. Cinaciguat ameliorates glomerular damage by reducing ERK1/2 activity and TGF-ß expression in type-1 diabetic rats.
    Czirok S, Fang L, Radovits T, Szabó G, Szénási G, Rosivall L, Merkely B, Kökény G.
    Sci Rep; 2017 Sep 11; 7(1):11218. PubMed ID: 28894114
    [Abstract] [Full Text] [Related]

  • 9. The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats.
    Reinke Y, Gross S, Eckerle LG, Hertrich I, Busch M, Busch R, Riad A, Rauch BH, Stasch JP, Dörr M, Felix SB.
    Eur J Pharmacol; 2015 Nov 15; 767():1-9. PubMed ID: 26407652
    [Abstract] [Full Text] [Related]

  • 10. Cinaciguat in combination with insulin induces a favorable effect on implant osseointegration in type 2 diabetic rats.
    Jia T, Wang YN, Zhang J, Hao X, Zhang D, Xu X.
    Biomed Pharmacother; 2019 Oct 15; 118():109216. PubMed ID: 31319371
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide.
    Salloum FN, Das A, Samidurai A, Hoke NN, Chau VQ, Ockaili RA, Stasch JP, Kukreja RC.
    Am J Physiol Heart Circ Physiol; 2012 Mar 15; 302(6):H1347-54. PubMed ID: 22268103
    [Abstract] [Full Text] [Related]

  • 13. Cinaciguat, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus.
    Chester M, Tourneux P, Seedorf G, Grover TR, Gien J, Abman SH.
    Am J Physiol Lung Cell Mol Physiol; 2009 Aug 15; 297(2):L318-25. PubMed ID: 19465519
    [Abstract] [Full Text] [Related]

  • 14. Stimulation of soluble guanylyl cyclase (sGC) by riociguat attenuates heart failure and pathological cardiac remodelling.
    Rüdebusch J, Benkner A, Nath N, Fleuch L, Kaderali L, Grube K, Klingel K, Eckstein G, Meitinger T, Fielitz J, Felix SB.
    Br J Pharmacol; 2022 Jun 15; 179(11):2430-2442. PubMed ID: 33247945
    [Abstract] [Full Text] [Related]

  • 15. Nitric oxide- and heme-independent activation of soluble guanylate cyclase attenuates peroxynitrite-induced endothelial dysfunction in rat aorta.
    Korkmaz S, Loganathan S, Mikles B, Radovits T, Barnucz E, Hirschberg K, Li S, Hegedüs P, Páli S, Weymann A, Karck M, Szabó G.
    J Cardiovasc Pharmacol Ther; 2013 Jan 15; 18(1):70-7. PubMed ID: 22914857
    [Abstract] [Full Text] [Related]

  • 16. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure.
    Breitenstein S, Roessig L, Sandner P, Lewis KS.
    Handb Exp Pharmacol; 2017 Jan 15; 243():225-247. PubMed ID: 27900610
    [Abstract] [Full Text] [Related]

  • 17. Irreversible Activation and Stabilization of Soluble Guanylate Cyclase by the Protoporphyrin IX Mimetic Cinaciguat.
    Kollau A, Opelt M, Wölkart G, Gorren ACF, Russwurm M, Koesling D, Mayer B, Schrammel A.
    Mol Pharmacol; 2018 Feb 15; 93(2):73-78. PubMed ID: 29138269
    [Abstract] [Full Text] [Related]

  • 18. Effects of soluble guanylate cyclase activation on heart transplantation in a rat model.
    Loganathan S, Korkmaz-Icöz S, Radovits T, Li S, Mikles B, Barnucz E, Hirschberg K, Karck M, Szabó G.
    J Heart Lung Transplant; 2015 Oct 15; 34(10):1346-53. PubMed ID: 26210750
    [Abstract] [Full Text] [Related]

  • 19. Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockade.
    Ott IM, Alter ML, von Websky K, Kretschmer A, Tsuprykov O, Sharkovska Y, Krause-Relle K, Raila J, Henze A, Stasch JP, Hocher B.
    PLoS One; 2012 Oct 15; 7(8):e42623. PubMed ID: 22900035
    [Abstract] [Full Text] [Related]

  • 20. Benign prostatic hyperplasia/obstruction ameliorated using a soluble guanylate cyclase activator.
    Zabbarova IV, Ikeda Y, Kozlowski MG, Tyagi P, Birder LA, Chakrabarty B, Perera SK, Dhir R, Straub AC, Sandner P, Andersson KE, Drake MJ, Fry CH, Kanai AJ.
    J Pathol; 2022 Apr 15; 256(4):442-454. PubMed ID: 34936088
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.